Alkem Laboratories Ltd.
ALKEMNSEHealthcarePharmaceuticals & DrugsMid Cap
₹5,373.5
▲ 0.03%
loading…
61
Composite
The company is one of India's foremost global pharmaceutical company. The company is engaged in the development, manufacture and marketing of pharmaceuticals with operational footprints across different countries. In India, it has a formidable presence in several therapy segments and consistently features amongst the top ten pharmaceutical companies. Steered by its industry experience of over four decades, it offers high-quality branded generics, generic drugs, active pharmaceutical ingredients and nutraceuticals.
Q-DITS fundamental score
61Composite
Growth
65
Profitability
61
Valuation
31
Quality
76
Solvency
70
Earnings
52
Key metrics
MCap
₹64.3K Cr
TTM PE
27.9x
Industry PE
38.2x
TTM EPS
₹192.51
Book Value
₹1,155.87
Face Value
₹2
Div Yield
0.99%
PEG
0.87x
PB
4.9x
ROE
19.9%
ROCE
21.6%
EBITDA mgn
15.6%
D/E
0.09
Int. Cover
21.8x
Curr. Ratio
2.73x
EPS
₹181.14
Growth — CAGR across horizons
| Metric | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|
| Net Sales | 13.5% | 8.3% | 10.7% | 11.3% |
| EBITDA | 19.6% | 23.1% | 9.1% | 13.4% |
| Net Profit | 12.9% | 32% | 9.1% | 12.7% |
Score snapshot
Piotroski
7/9
Altman Z
2.11
Quality
76
Growth
65.4
Valuation
31
Earn. Qual
51.7
PEAD
0
SURGE
0
Loading price data…
Loading delivery data…
Revenue, profitability & returns
Revenue & Net Profit (₹ Cr)
RevenueNet Profit
Margins (%)
EBITDA%PAT%
Return ratios (%)
ROEROCEROA
Annual financials — last 10 years
Tap a row to expand the full chart
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›RevenueCr | 4,925 | 5,688 | 6,392 | 7,357 | 8,344 | 8,865 | 10,634 | 11,599 | 12,668 | 12,965 | |
| ›EBITDACr | 1,093 | 1,111 | 1,124 | 1,202 | 1,578 | 2,176 | 2,201 | 1,723 | 2,435 | 3,006 | |
| ›EBITDA margin | 21.7% | 19% | 13.1% | 11.2% | 12.7% | 16.6% | 14.5% | 10.2% | 13.2% | 15.6% | |
| ›Net profitCr | 752 | 905 | 638 | 774 | 1,149 | 1,618 | 1,680 | 1,007 | 1,811 | 2,216 | |
| ›PAT margin | 14.9% | 15.5% | 7.4% | 7.2% | 9.3% | 12.3% | 11% | 5.6% | 9.3% | 11.5% | |
| ›EPS₹ | ₹62.03 | ₹74.62 | ₹52.78 | ₹63.61 | ₹94.28 | ₹132.58 | ₹137.65 | ₹82.32 | ₹150.21 | ₹181.14 | |
| ›Revenue growth | 31.6% | 15.5% | 12.4% | 15.1% | 13.4% | 6.2% | 20% | 9.1% | 9.2% | 2.3% | |
| ›PAT growth | 92.1% | 20.3% | -29.4% | 21.2% | 48.6% | 40.8% | 3.9% | -40.1% | 79.9% | 22.3% | |
| ›ROE | 22.5% | 22.2% | 13.7% | 15% | 19.8% | 23.9% | 21% | 11.4% | 18.7% | 19.9% | |
| ›ROCE | 23.1% | 21.3% | 17.9% | 16.5% | 18.7% | 22.6% | 18.7% | 13.1% | 19.5% | 21.6% | |
| ›ROA | 14.6% | 16.6% | 9.9% | 10.7% | 13.9% | 16.7% | 14.5% | 8% | 13.7% | 14.8% | |
| ›P/E | 22x | 29.6x | 37.5x | 27.5x | 24.7x | 20.9x | 26.3x | 41.3x | 32.9x | 26.9x | |
| ›P/B | 4.4x | 5.9x | 4.9x | 3.9x | 4.5x | 4.5x | 5x | 4.5x | 5.7x | 4.9x | |
| ›D/E | 0.2 | 0.1 | 0.2 | 0.2 | 0.3 | 0.2 | 0.3 | 0.1 | 0.1 | 0.1 | |
| ›Current ratio | 1.8x | 1.7x | 1.7x | 1.9x | 1.7x | 1.9x | 1.8x | 2.3x | 2.6x | 2.7x | |
| ›Interest cover | 14x | 22.4x | 17.7x | 18.5x | 20.4x | 32.3x | 36.2x | 13.2x | 19x | 21.8x |
Quarterly results
Tap a row to expand the full chart
| Metric | Trend | 2023-12 | 2024-03 | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›RevenueCr | 3,324 | 2,936 | 3,032 | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 | |
| ›Rev growth YoY | 9.3% | 1.1% | 2.2% | -0.7% | 1.5% | 7.1% | 11.2% | 17.2% | 10.7% | 14.6% | |
| ›EBITDACr | 708 | 402 | 609 | 753 | 759 | 391 | 739 | 921 | 828 | 517 | |
| ›EBITDA margin | 21.3% | 13.7% | 20.1% | 22% | 22.5% | 12.4% | 21.9% | 23% | 22.2% | 14.4% | |
| ›Net profitCr | 604 | 304 | 550 | 702 | 641 | 323 | 668 | 780 | 654 | 252 | |
| ›PAT growth YoY | 31.4% | 349.9% | 91.2% | 14.2% | 6% | 6.1% | 21.5% | 11.1% | 2% | -22.1% | |
| ›EPS₹ | ₹49.77 | ₹24.56 | ₹45.6 | ₹57.6 | ₹52.35 | ₹25.58 | ₹55.56 | ₹64 | ₹53.2 | ₹19.78 |
Balance sheet — last 10 years (₹ Cr)
Tap a row to expand the full chart
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›Shareholders' equityCr | 4,468 | 4,864 | 5,439 | 6,161 | 7,377 | 8,638 | 9,045 | 10,312 | 11,985 | 13,820 | |
| ›ReservesCr | 4,443 | 4,839 | 5,414 | 6,135 | 7,352 | 8,613 | 9,021 | 10,269 | 11,925 | 13,796 | |
| ›Total borrowingsCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| ›InvestmentsCr | 1,152 | 678 | 489 | 406 | 475 | 1,223 | 1,036 | 766 | 2,509 | 0 | |
| ›Total assetsCr | 4,878 | 5,281 | 5,990 | 6,701 | 7,915 | 9,264 | 10,050 | 11,580 | 13,732 | 20,873 | |
| ›Current assetsCr | 2,915 | 4,013 | 4,204 | 5,488 | 6,923 | 8,434 | 8,606 | 10,412 | 10,811 | 12,211 | |
| ›Current liabilitiesCr | 1,690 | 2,383 | 2,218 | 3,245 | 3,604 | 4,805 | 3,707 | 3,995 | 3,959 | 4,783 | |
| ›Trade payablesCr | 741 | 961 | 962 | 954 | 1,069 | 1,173 | 1,165 | 1,748 | 1,839 | 2,244 | |
| ›Gross blockCr | 1,977 | 2,604 | 3,026 | 3,607 | 3,723 | 4,186 | 4,050 | 4,544 | 4,720 | 2,695 |
Cash flow statement (₹ Cr)
Tap a row to expand the full chart
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›Operating CF (CFO)Cr | 471 | 266 | 780 | 585 | 1,265 | 1,111 | 1,683 | 1,948 | 1,913 | 1,963 | |
| ›Investing CF (CFI)Cr | -286 | -357 | -316 | -741 | -999 | -1,435 | 113 | -1,008 | -1,299 | -1,667 | |
| ›Financing CF (CFF)Cr | -138 | 85 | -379 | 79 | -272 | 380 | -1,761 | -1,145 | -811 | -503 | |
| ›Net cash changeCr | 47 | -7 | 84 | -77 | -5 | 55 | 35 | -205 | -197 | -208 | |
| ›Closing cashCr | 167 | 167 | 249 | 176 | 174 | 232 | 274 | 66 | -120 | -342 |
Cash flow components
CFO · CFI · CFF (₹ Cr)
CFOCFICFF
Q-DITS scorecard
Composite score
61
Quality (25%)76
Growth (25%)65.4
Valuation (20%)31
Piotroski (15%)78
Earnings Quality (10%)51.7
Momentum (5%)—
Weighted blend, rescaled to the components available for this stock.
Piotroski F-Score
7/9
✓ROA positiveROA 14.77%
✓CFO positiveCFO ₹1963.03 Cr
✓ROA improving13.66% → 14.77%
✗CFO > PAT (low accruals)CFO 1963.03 vs PAT 2216.0
✓Leverage decreasedD/E 0.12 → 0.09
✓Liquidity improvedCR 2.61 → 2.73
✓No share dilutionEPS 150.21 → 181.14
✓Margin improvedEBITDA mgn 13.19% → 15.57%
✗Asset turnover upAsset TO 1.46 → 1.29
Altman Z-Scoregrey
2.11
X1
0.356
X2
0.661
X3
0.127
X4
0.662
X5
0.621
>2.9 safe · 1.23–2.9 grey · <1.23 distress
Quality
76/100
ROE
19.9%
ROCE
21.6%
Margin
11.5%
Debt
0.1
Int. cover
21.8x
Growth
65.4/100
Revenue 3Y
8.3%
Profit 3Y
32%
EPS
20.6%
Valuation
31/100
PE
26.9x
PB
4.9x
EV/EBITDA
19.2x
vs universe median: PE 25.6x · PB 2.81x · EV 13.41x
Earnings quality
51.7/100
CFO₹1,963 Cr
PAT₹2,216 Cr
Accrual ratio0.012
CFO/PAT0.89x
PEAD · SURGE
0 / 0
Revenue SUE1.42
EPS SUE-2.15
Latest quarter2026-03
Rev growth YoY14.6%
Documents & filings
Loading documents…
Peer comparison
| Company | MCap (Cr) | Revenue | PAT | PE | PB | ROE% | ROCE% | D/E |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,40,794 | 58,462 | 11,565 | 38.4x | 5.3x | 16.2 | 19.9 | 0.03 |
| Divi's Laboratories Ltd. | 1,78,956 | 10,560 | 2,568 | 69.7x | 10.7x | 15.4 | 20.5 | 0 |
| Torrent Pharmaceuticals Ltd. | 1,49,820 | 13,980 | 2,138 | 69.3x | 17.9x | 26.8 | 19.3 | 1.76 |
| Cipla Ltd. | 1,09,370 | 28,163 | 3,870 | 28.2x | 3.2x | 11.8 | 16 | 0.01 |
| Lupin Ltd. | 1,07,537 | 27,958 | 5,355 | 20.2x | 4.8x | 21.1 | 22 | 0.3 |
| Zydus Lifesciences Ltd. | 1,06,823 | 27,148 | 5,026 | 21.2x | 4x | 21.1 | 26.1 | 0.13 |
| Dr. Reddy's Laboratories Ltd. | 1,06,133 | 33,700 | 4,144 | 25.3x | 2.8x | 18.6 | 23.3 | 0.14 |